Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença LB, Oliveira TM, Vauchier C, Pereira Mestre R, Modesti M, Patrikidou A, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E.
Nuzzo PV, et al. Among authors: valenca lb.
Ther Adv Med Oncol. 2023 Mar 3;15:17588359231156147. doi: 10.1177/17588359231156147. eCollection 2023.
Ther Adv Med Oncol. 2023.
PMID: 36895852
Free PMC article.